Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent Technologies Inc. : - Clinical Utility of ALK Fusion Detection by Liquid Biopsy

07/28/2021 | 09:44am EST

Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled 'Clinical Utility of Next-Generation Sequencing-Based ctDNA Testing for Common and Novel ALK Fusions'.

The study, jointly published by Resolution Bioscience (now a part of Agilent) and Memorial Sloan Kettering Cancer Center (MSK), describes the use of plasma ctDNA NGS to detect novel anaplastic lymphoma kinase (ALK) fusions, and to serially monitor the development of mechanisms of resistance in response to targeted therapy.

The development of drugs that target ALK fusions represented a crucial milestone in the advent of precision oncology; ALK fusions have been reported in approximately 5% of patients with NSCLC1. The use of next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) to detect ALK fusions is an emerging alternative to tissue-based methodologies such as fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and tissue-based NGS. Compared to tissue tests, liquid biopsy has the advantage of not requiring an invasive tissue biopsy, having a significantly shorter turnaround time, and allowing for serial testing that can track tumor response and detect tumor evolution2,3.

Katharine Knobil, M.D., chief medical officer at Agilent Technologies, discussed the importance of the findings. 'A number of targeted drugs now exist for the treatment of patients with ALK fusions. However, detecting ALK fusions using liquid biopsy is challenging,' Knobil said. 'This paper demonstrates the capability of the Resolution platform to detect ALK fusions from the blood of patients with NSCLC in a non-invasive and timely manner. Most importantly, it was able to demonstrate clinical benefit by guiding patients to positive clinical responses.'

Bob Li, MD, Ph.D., MPH, co-director of the Thoracic Liquid Biopsy Program at MSK, remarked, 'As a continuation of our multiyear collaboration with Resolution Bioscience, this study provides further evidence for the clinical utility of liquid biopsy, here with a focus on ALK fusion detection, for which there is limited data. In addition to detecting common EML4-ALK fusions, liquid biopsy was also able to detect resistance mechanisms like MET amplifications and discover novel fusion partners, including a patient with a PON1-ALK fusion. This patient was treated with alectinib based on the liquid biopsy result and had a durable response.'

Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed core technology for circulating cell-free DNA NGS analysis. Resolution Bioscience's Liquid Biopsy assays are powered by the company's cell-free DNA (cfDNA) analysis platform, which includes targeted capture next-generation sequencing (NGS) biochemistry and tightly coupled, cloud-based bioinformatics. The Resolution Bioscience homologous recombination deficiency (HRD) assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration.

This study reinforces Agilent's commitment to partnering with leaders in clinical oncology through the continued development and application of key Resolution Bioscience diagnostics tools to provide valuable solutions that drive positive clinical responses.

Media Contact:

Naomi Goumillout

Tel: +1 978 314 1862

Email: naomi.goumillout@agilent.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about AGILENT TECHNOLOGIES, INC.
12/06Agilent Announces the Cary 3500 UV-Vis Spectrophotometer Compatibility with OpenLab
BU
11/23Agilent to Present at Evercore ISI Virtual Healthcare Conference
BU
11/23Stifel Adjusts Price Target for Agilent Technologies to $169 From $162, Maintains Hold ..
MT
11/23SVB Leerink Adjusts Agilent Technologies' Price Target to $175 from $170, Keeps Outperf..
MT
11/23Health Care Stocks Flat Ahead of Tuesday's Opening Bell
MT
11/22AGILENT TECHNOLOGIES : Prepared Remarks (opens in new window)
PU
11/22AGILENT : Fiscal Q4 Earnings Snapshot
AQ
11/22Agilent Technologies Fiscal Q4 non-GAAP EPS, Revenue Rise
MT
11/22AGILENT TECHNOLOGIES : Reports Fourth-Quarter and Fiscal Year 2021 Financial Results - For..
PU
11/22Earnings Flash (A) AGILENT TECHNOLOGIES Posts Q4 Revenue $1.66B, vs. Street Est of $1.6..
MT
More news
Analyst Recommendations on AGILENT TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 6 318 M - -
Net income 2021 1 075 M - -
Net Debt 2021 1 485 M - -
P/E ratio 2021 43,4x
Yield 2021 0,50%
Capitalization 45 853 M 45 853 M -
EV / Sales 2021 7,49x
EV / Sales 2022 6,92x
Nbr of Employees 17 000
Free-Float 100,0%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | A | US00846U1016 | MarketScreener
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 151,47 $
Average target price 173,80 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Boon Hwee Koh Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGILENT TECHNOLOGIES, INC.25.08%45 853
THERMO FISHER SCIENTIFIC33.59%245 196
DANAHER CORPORATION38.16%219 304
INTUITIVE SURGICAL, INC.17.94%115 663
SIEMENS HEALTHINEERS AG51.93%80 663
EDWARDS LIFESCIENCES CORPORATION20.38%69 900